Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB0,00
PKN86,7986,8-0,25
Msft-0,94
Nokia4,0614,255-0,15
IBM-0,97
Mercedes-Benz Group AG50,9250,93-1,05
PFE3,63
23.07.2025 1:38:58
Indexy online
AD Index online
select
AD Index online
 

  • 22.07.2025 21:55:48
Trinity Bio Sp ADR (NASDAQ Cons)
Poslední obchod Změna (%) Změna (USD) Objem obchodů (ks)
0,72 0,00 0,00 57 402
After-hours23.07.2025 1:38:01
Poslední obchod Nákup / Prodej Změna (%) Změna (USD)
0,71 - - 0,00 0,00
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 23.07.2025
Popis společnosti
Obecné informace
Název společnostiTrinity Biotech PLC (ADR)
TickerTRIB
Kmenové akcie:ADR
Kmenové akcie:Ordinary Shares
RICTRIB.O
ISIN-
Poslední známé roční výsledky31.12.2024
Poslední známé čtvrtletní výsledky31.12.2024
Počet zaměstnanců k 31.12.2024 401
Akcie v oběhu k 31.12.2024 30 566 057
MěnaUSD
Kontaktní informace
UliceIda Business Park, Bray, Co Wicklow
MěstoDUBLIN
PSČ18
ZeměIreland
Kontatní osobaEric Ribner
Funkce kontaktní osobyInvestors Relations
Telefon35 312 769 800
Fax35312769888
Kontatní telefon16 028 899 700

Business Summary: Trinity Biotech plc is an Ireland-based commercial stage biotechnology company. The Company is focused on human diagnostics and diabetes management solutions, including wearable biosensors. The Company develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market and has also entered the wearable biosensor industry. It intends to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product. Its products are used to detect infectious diseases and to quantify the level of Hemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. The Company, through EpiCapture Limited, is also developing a non-invasive test for monitoring the risk of aggressive prostate cancer. The Company sells its products direct in the United States and through a network of international distributors.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2024, Trinity Biotech PLC (ADR) revenues increased 8% to $61.6M. Net loss before extraordinary items decreased 15% to $31.2M. Revenues reflect Point of care segment increase of 92% to $17.4M, Ireland segment increase of 67% to $19.8M. Lower net loss reflects Americas segment loss decrease of 67% to $5.1M, Unallocated segment loss decrease of 6% to $3.4M.
Odvětvová klasifikace
TRBC2009Medical Equipment / Supplies / Distribution
TRBC2012Laboratory Diagnostic & Testing Substances
RBSS2004Medical Equipment, Supplies & Distribution
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSIn-Vitro Diagnostic Substance Manufacturing
NAICSMedical Laboratories
NAICS2007In-Vitro Diagnostic Substance Mfg
NAICS2007Medical Laboratories
NAICS1997InVitro Diagnostic Substance Manufacturing
NAICS1997Medical Laboratories
SICDiagnostic Substances
SICDiagnostic Substances
SICMedical Laboratories



  • Poslední aktualizace: 23.07.2025
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Executive Chairman of the Board, Interim Chief Commercial OfficerPasquale Natuzzi8501.01.1972
Chief Executive Officer, Executive DirectorAntonio Achille5401.06.2021
Chief Financial OfficerCarlo Silvestri4801.01.2022
Group Chief Operating OfficerDomenico Ricchiuti48
Group Chief Human Resources, Organization and Legal OfficerMario de Gennaro59
Group Chief Technology & Digital Innovation Officer, Chief Front Office Customer Care OfficerPierangelo Colacicco56
Group Chief Marketing & Communication OfficerDaniele Tranchini65
Executive Director, Chief Trade & Contract OfficerPasquale Junior Natuzzi3412.06.2020
Group Regional Manager - Emerging MarketsFrancesco Amendola4801.01.2023
Group Chief Retail OfficerDiego Babbo5301.01.2023